Trial Profile
Randomized, Parallel-group, Double-blind Multi-center Phase III Study to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers, in Elderly and Young Adults.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine liposomal (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Crucell
- 05 Nov 2010 New trial record